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THE cytokines IL-1 and TNF-g are involved in inflamma-
tion and their production is stimulated by various agents,
especially endotoxin (LPS). Here, using the human IL-1
receptor antagonist (IL-1RA) and a new monoclonal anti-
body (mAb 7Fll) to rabbit TNF, the role of endogenous
ILol and TNF production in acute (3h) leukocyte
(PMNL) recruitment to dermal inflammation in rabbits
has been studied. IL-1RA inhibited by 27% the PMNL
accumulation in reactions induced by killed Escherichia
coil (p < 0.05) but not by LPS. The monoclonal antibody
to TNF inhibited by 27% and 38% (p < 0.002) the PMNL
accumulation in LPS and E. coil reactions respectively,
but a combination of the mAb with IL-1RA was not more
effective. Treatment ofhuman umbilical vein endothelium
with LPS for 3 h activated endothelium to induce PMNL
transendothelial migration in vitro, which was not
inhibited by IL-1RA, antibody to TNF-g, IL-1 or to IL-8.
In conclusion, TNF and IL-1 may partially mediate acute
PMNL infiltration in vivo to LPS and Gram negative
bacteria, but there is a major IL-1/TNF independent
mechanism, at least in dermal inflammation, which may
be due to direct LPS activation of the microvasculature or
perhaps the generation of cytokines other than IL-1 and
TNF.
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Introduction
The acute inflammatory reaction is usually
characterized by rapid, early (1-2 h) infiltration of
the tissue by polymorphonuclear leukocytes
(PMNL) and an increase in vascular permeability.
Subsequently, vascular and tissue injury may result.
A host of mediators and mediator systems have
been implicated in this response, including
vasoactive amines, lipids and proteins, some of
which are generated by activation of cascade
systems such as the complement and coagulation
pathways.
2 More recently, some members of the
cytokine family of proteins have been found to have
inflammatory properties.
3-6 Among these, inter-
leukin-1 (IL-1) and turnout necrosis factor cz (TNF)
are synthesized rapidly, especially by monocytes,
resident tissue macrophages and to a lesser extent by
PMNL, lymphocytes, and connective tissue cells. 7,s
Both IL-1 and TNF can subsequently active other
cells, such as vascular endothelium to become
adhesive for PMNL and mononuclear leukocytes,
and to induce the synthesis of cytokines directly
chemotactic for leukocytes such as IL-8 and
monocyte chemotactic protein-1 (MCP-1).6’9
Among the cytokines, IL-1 and TNF-oq are likely
the earliest cytokines in the cytokine cascade to be
synthesized during acute inflammatory reactions.
It is now well recognized that vascular and tissue
injury during acute inflammation is in part
dependent on the invasion of the involved tissues
by PMNL. As part of on-going investigations into
the mechanisms regulating PMNL migration into
inflammation, an acute dermal inflammation model
in rabbits has been used in this study. The role of
endogenously produced IL-1 and TNF in the acute
PMNL accumulation in dermal inflammatory
reactions induced by a variety of agents has been
investigated. For this purpose, recombinant human
IL-1 receptor antagonist (IL-1RA)1’11 and a new
monoclonal antibody (mAb) which neutralizes
rabbit TNF, were employed to block the activity of
endogenously produced rabbit IL-1 and TNF. The
results indicate that of the reactions studied, TNF
in particular, contributes significantly but only to a
minor extent, to the PMNL infiltration during
killed Escherichia co/i and endotoxin (LPS) induced
inflammation.
Materials and Methods
Dermal inflammatory reactions: New Zealand White
rabbits of either sex (3-4 kg) had their backs shaved
the day before experiments. On the day of study,
51Cr labelled blood leukocytes (see below), were
injected i.v. and up to 56 skin sites were injected
intradermally (i.d.) (0.2ml) with inflammatory
stimuli in a random pattern using 30-gauge needles
as described previously, az’13 Three hours later, the
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animal was sacrificed with an intravenous (i.v.)
overdose of pentobarbital, the skin was removed,
and the lesions punched out using a 16 mm leather
punch. Radioactivity in the skin samples was
determined in an LKB gamma spectrometer.
Inflammatory stimuli: Recombinant human inter-
leukin-1 (IL-I), which had a specific activity of
4 x 107U/mg, was a gift from Dr D. Urdal
(Immunex Corp., Seattle, WA, USA). Recombinant
human tumour necrosis factor (TNF-) (specific
activity of 5 x 107U/mg) was a gift from
Genentech Inc. (South San Francisco, CA, USA).
All of these cytokines contained <1 ng of
endotoxin/mg. Each of the cytokines were diluted
immediately before use in 0.1% endotoxin-free
human serum albumin (Connaught Labs., Don
Mills, Ontario, Canada) in phosphate buffered saline
(HSA-PBS). E. coli 0111 lipopolysaccharide (LPS)
was from List Biologicals (Campbell, CA). E. coli
018.K1HT, an isolate from an infant with
meningitis, was grown in broth culture, killed with
formaldehyde, washed, and the number of bacteria
were estimated spectrophotometrically as described
previously,
a2 Zymosan activated plasma (ZAP) was
generated as previously
a4 by incubation of hepar-
inized (5 U/m1) rabbit plasma for 60 rain (37C)
with 5 mg/ml Zymosan A (Sigma Chemical Co., St.
Louis, MO, USA) followed by removal of zymosan
by centrifugation.
The reversed dermal Arthus reaction was
induced by i.v. injection of 10 mg human pyrogen
free IgG (Sandoglobulin, Sandoz Pharmaceuticals,
Dorval, Quebec, Canada), 1 h prior to i.d. injection
of heat inactivated hyperimmune rabbit antiserum
to human IgG. a3’a5 Rabbit TNF-0 was purified from
rabbit macrophage culture supematants. Briefly,
rabbit peritoneal macrophages were harvested,
following pentobarbital euthanasia, by peritoneal
lavage with 300ml Tyrodes solution (2U/ml
heparin), 5 days following i.p. injection of 35 ml
sterile light mineral oil. a6 The cells were adhered in
175cm
/ tissue culture flasks (Falcon, Fisher
Scientific Co., Dartmouth, Nova Scotia, Canada)
for 2 h in RPMI-1640 (Gibco, Grand Island, NY,
USA) 5% heat inactivated rabbit serum, then rinsed
to remove non-adherent cells. The adherent cells,
which were > 95% macrophages, were stimulated
with LPS (30 ng/ml) in RPMI-1640 for 6 h at 37C
in 5% CO2. The supematant was then harvested,
dialysed against water, concentrated by lyophiliza-
tion 100-200-fold and applied to a Superose-12
FPLC column (Pharmacia Fine Chemicals, Dorval,
Quebec) equilibrated with 0.3 M NaC1-0.01 M
Na2HPO4, pH 7. Fractions eluting between 40 and
50 kilodaltons (kDa), were rich in TNF activity as
assayed by cytotoxicity for the TNF sensitive L929
mouse fibroblast line. a7 The fractions which
eluted between 12 and 20 kDa were devoid of IL-1
activity.
8
Anticytokine reagents: Highly purified human re-
combinant interleukin-1 receptor antagonist (IL-
1RA) was a kind gift from Dr R. C. Thompson
(Synergen Inc., Boulder, CO). The rat mAb
7Fll, which neutralized rabbit macrophage TNF-0
and lymphocyte derived TNF-fl bioactivity, was rat
isotype IgGa according to a commercially available
isotyping kit (Serotec Canada, Toronto, Ontario).
This antibody was generated by immunization of
AO strain male rats with partially purified
TNF-z (40-50 kDa Superose-12 fractions). The
immunization protocol consisted of covalently
coupling 3-5 #g of protein to 1 cm2 pieces of the
APT form of Transabind paper (Schleicher and
Schuell Ltd, Keene, NH, USA) according to the
instructions of the manufacturer. The immobilized
antigen was introduced surgically under anaesthesia
into the peritoneal cavity of the rats every 10-14
days together with i.p. injection of polyadenosine-
polyuridine (800/tg) (Sigma Chemical Co.) as an
adjuvant,a9’2 After a total of four such immuniza-
tions, the animals had neutralizing activity in their
serum for rabbit TNF-. After a rest period, one rat
was booster immunized by intrasplenic injection of
5g of partially purified antigen. Four days later
the spleen was removed, and splenocytes were fused
with the P3U1 mouse myeloma using polyethylene
glycol 1450 (Merck Frosst, Montreal, Quebec)
according to standard techniques.
21 Following
fusion, the lymphocytes were plated into flat
bottom 96-well microtitre plates (NUNC, Gibco) at
a density of2 x 10 cells/well in Dulbecco Modified
Eagle’s Medium (DMEM; Gibco) with non-
essential amino acids, Na pyruvate and 10% foetal
calf serum (FCS; Hyclone, Logan, UT, USA), into
wells containing a mixture of 5 x 105 irradiated
mouse thymocytes and splenocytes prepared 24 h
previously as feeder cells.
2a Supernatants from
hybridoma-containing wells were screened for
neutralization of the cytotoxic activity of rabbit
TNF-0q and one of the positive hybridomas, 7Fll
was cloned by limiting dilution. This mAb
neutralized both rabbit macrophage derived TNF-z
and mitogen (Con A and PHA). stimulated rabbit
lymphocyte derived TNF activity, presumably
TNF-/.
7 However, mAb 7Fll was specific for
rabbit TNF in that it did not neutralize mouse, rat
or human TNF0 activity. The mAb was purified by
affinity chromatography on Protein G Sepharose
from cells grown in serum free medium (DMEM
supplemented with 2% Nutridoma, Boehringer
Mannheim, Montreal, Quebec). Binding of the
IgG was at pH7 in PBS and elution was with 0.1 M
glycine-HC1, pH 3.5 followed by pH 2.7 buffers, as
recommended by the manufacturer (Pharmacia Fine
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Chemicals, Dorval, Quebec). The purified mAb
preparation had a titre of 30000 neutralizing
units/ml.
Polyclonal rabbit antibody to human IL-10 and
IL-1/ and to human TNF-0 were kind gifts from
Dr C. Dinarello (Tufts University, Boston, MA,
USA). Polyclonal goat antibody to human IL-8 was
a gift from Sandoz Pharmaceuticals (Vienna,
Austria). These antibodies were all neutralizing and
were used in a dilution of 1:100 in the in vitro assay
system. Neutralizing mAb to human TNF- was a
kind gift from Dr M. Sheppard (Genentech Inc.,
South San Francisco, CA). It had a neutralizing titre
of 8 x 106 NU/mg.
Measurement of rabbit leukocyte accumulation in dermal
inflammation" The quantitation of leukocyte accumu-
lation in dermal inflammatory reactions has been
described in detail previously. 13’18 Briefly, 30 ml of
acid-citrate dextrose anticoagulated blood was
collected from the rabbit and red blood cells were
removed by hydroxyethyl cellulose sedimentation
(Fluka Chemical Co., Ronkonkoma, NY). The
leukocytes were labelled with NaiS1CrO4 (Amer-
sham Inc., Oakville, Ontario), washed with Cap+,
Mg
2+ free Tyrodes’ buffer-10% ACD plasma, and
injected i.v. just prior to the injection (i.d.) of
inflammatory stimuli in skin sites. It has been
shown13’18 that results with this mixed leukocyte
population, labelled with 51Cr are comparable to
that obtained with purified 51Cr-labelled PMNLs, as
long as the leukocyte infiltration into the acute
inflammatory lesions is composed of >90%
PMNLs and no local haemorrhage in the site
occurs. Both of these criteria were met in this work
during the period of study of the lesions (3 h). The
51Cr cpm in the skin lesions was converted to
number of PMNLs x l06 accumulated/site by
standardizing values relative to the response to
zymosan activated plasma (ZAP) at 10 x 106
PMNL/site. This value is based on the mean
response (10 +/- 0.8 x 106 PMNL/site; SEM) in 30
rabbits, in previous studies in which blood
PMNL specific activity (number of PMNL/cpm)
was determined after 5Cr-leukocyte injection,
using hydroxyethylcellulose sedimentation of red
cells and Percoll’s density gradient purification of
the PMNLs. The PMNL specific activity measure-
ment allowed for conversion of SCr content in skin
sites to number of PMNL/site as described. 13’18
Endothelial cell cultures: Human umbilical vein en-
dothelial cells (HUVE) were obtained using
collagenase digestion as described by Jaffe et a]o22
and described in detail previously.
3 Briefly, isolated
cells were grown to confluence in gelatin coated
flasks in RPMI-1640-20% FCS, supplemented with
Endothelial Cell Growth Supplement (25 #g/ml)
(Collaborative Research, Lexington, MA), Na
pyruvate (1 mM), 2-mercaptoethanol (2ME)
(50/M), heparin (90 #g/ml) and penicillin/strepto-
mycin. HUVE were then gently trypsinized and
plated on gelatin-fibronectin coated polycarbonate
filters bearing 3 #m pores in 24-well transwell
culture plate inserts (6.5mm) (Costar Corp.,
Cambridge, MA). After 6 days of culture in the
above medium, endothelium formed a tight
monolayer and permeability barrier separating an
upper chamber of 100 #1 volume from a lower
chamber (24-well plate macrowell) containing
600 #1 medium as described previously.
2
Human po&morphonuclear leukocyte purification: Human
PMNL were purified from acid citrate dex-
trose-heparin anticoagulated peripheral venous
blood of healthy donors as described previously.
23
Briefly, red cells were sedimented with 6%
dextran-saline (Abbott Labs, Montreal, Quebec),
leukocyte rich plasma was collected and leukocytes
were labelled with NaiSCrO4 (Amersham Inc.).
PMNLs were then purified by discontinuous
Percoll’s gradient centrifugation, washed, and
resuspended to 3 x 106 PMNL/ml in RPMI-1640-
0.5% HSA-10mM Hepes pH 7.2. This method
yielded PMNL of _> 95% purity with essentially no
red cell contamination and >_98% cell viability.
In vitro PMNL transendothelial migration assay: For
assays, HUVE monolayers were handled according
to the previously published protocol.
23 In this
study, HUVE were stimulated by addition to the
lower chamber of various concentrations of LPS in
fresh RPMI-1640-10% FCS. After stimulation,
monolayers and upper and lower chambers were
rinsed, the medium in the lower chamber was
exchanged (600/il) for RPMI-1640-HSA-Hepes,
and the 51Cr-PMNL suspension (100 #1) was loaded
above the monolayer/filter, and incubated at 37C
in 5% COg. After 75 min, migration was stopped
by washing the surface above the monolayer with
RPMI-1640 to remove non-adherent PMNLs, and
the undersurface of the filter was rinsed with 2 ml
of ice-cold PBS-0.2% EDTA solution and collected
into the lower compartment. The PMNLs which
migrated into the lower compartment and those
which detached from the undersurface of the filter
by washing were lysed with 0.5% Triton X 100 to
release the 51Cr. The 51Cr content of the lower
compartment (medium+PBS-EDTA wash of filter
undersurface) represented migrated PMNLs. The
results are expressed as a percentage of total added
5Cr-PMNL in the lower compartment.
Statistical ana&sis: Statistical analysis of results was
performed by ’paired’ Student’s t-test.
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FIG. 1. The effect of IL-1 receptor antagonist and antibody to TNF on
dermal PMNL accumulation. Skin sites on rabbits were injected (i.d.)
with human IL-1, IL-1/t (2 rig/site), rabbit TNF- (500 U/site), E. coil
LPS (5 ng/site) or killed E. coil (107/site) together with control
(HSA-PBS or irrelevant mAb), IL-1RA (400ng), mAb to TNF
(1000NU), or both reagents in parallel in each rabbit. PMNL
accumulation was quantitated with 51Cr-PMNL for 3 h after initiation of
the reactions. Values are means -I-SEM of five experiments performed
with triplicate or quadruplicate replicates. *p < 0.05; **p < 0.002 by
paired Student’s t-test, r-l, control; I1, IL-1RA; [], mAb to TNF; M,
IL-1RA+mAb to TNF.
Results
Effect of IL-1 receptor antagonist and antibody to TNF on
derma/PMNL infiltration: In initial experiments the
eflqcacy of recombinant human IL-1 receptor
antagonist (IL-1RA) and the mAb to rabbit TNF
for blocking the in vivo activity of IL-1, and rabbit
TNF- for inducing PMNL accumulation in skin
sites were tested. As can be seen in Fig. 1, the
injection of 2 ng of recombinant human 1L-1 or
IL-lfl or partially purified rabbit macrophage
derived TNF-0, induced marked PMNL accumula-
tion during the first 3 h following i.d. injection.
Control injections of HSA-PBS (data not shown)
did not cause PMNL accumulation (0.2 _+ 0.05 x
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FIG. 2. The effect of IL-1 receptor antagonist and antibody to TNF on
dermal PMNL accumulation. Skin sites were injected i.d. with zymosan
A (2 mg), zymosan activated plasma (ZAP, 25%) or antiserum to human
IgG (1:8) following i.v. injection of human IgG, to induce the reversed
Arthus reaction. Other sites were injected with these agents in
combination with IL-1 RA or mAb to TNF as in Fig 1. Values are means
-I-SEM of three experiments. Key as for Fig "1.
106; uninjected skin 0.15 +__ 0.02 x 106 PMNL per
site). These HSA-PBS control values were
subtracted from all the values shown in Figs 1
and 2. The simultaneous injection of IL-1RA in a
dose of 400 ng per site, together with either IL-I
or IL-lfl, almost completely blocked the PMNL
accumulation in these sites. Similarly, the addition
of mAb to rabbit TNF- at a dose of 1000 NU per
injection site, virtually eliminated the PMNL
recruiting activity of 500 units of rabbit TNF-. In
cross inhibition studies the rabbit mAb to TNF did
not inhibit the activity of IL-I or IL-lfl for
recruiting PMNL into skin sites and vice versa, the
human IL-1RA did not inhibit (<10% inhibition)
the activity of rabbit TNF- for inducing PMNL
accumulation (not shown).
We next investigated the effects of IL-1RA and
mAb to TNF on the accumulation ofPMNL in skin
sites in the rabbits injected with E. coli LPS or killed
E. coil bacteria. As can be seen on the lower panel
in Fig. 1, the leukocyte accumulation induced by
LPS was not significantly inhibited by the
co-injection of IL-1RA, but was significantly
inhibited by mAb to rabbit TNF. The combination
of IL-1RA with mAb to TNF did not result in
greater inhibition than did mAb to TNF alone. In
response to i.d. injection of killed E. coli, both
IL-1RA and TNF mAb significantly inhibited
PMNL accumulation. The combination of IL-1RA
with anti-TNF did not inhibit to any greater extent
than either alone. In these experiments PMNL
accumulation was measured during the first 3 h after
i.d. injection of the skin sites, since it has been
shown previously that maximum PMNL accumula-IL-1 and TNF in PMNL infiltration
tion occurs during this time in these types of
lesions. 12 All combinations of agents were studied
in the same rabbit with triplicate or quadruplicate
skin sites being injected and statistical analysis was
by paired t-test. The dose of IL-1RA and mAb to
TNF were optimized for inhibitory activity and the
level of inhibition with IL-1RA did not increase
upon increasing the dose of IL-1RA to 1000 rig/site
or by increasing the mAb dose to 2500 NU per site.
The effect of IL-1RA and mAb to TNF on three
other inflammatory reactions was also studied,
namely that induced by i.d. injection of zymosan
particles, by the reversed passive Arthus reaction
and by ZAP, the active principle of which is
CSade Arg.
14 As shown in Fig. 2, neither IL-1RA nor
TNF mAb, nor a combination of both agents
inhibited the PMNL accumulation induced by
zymosan, ZAP or the Arthus reaction.
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FIG. 3. The effect of LPS on human PMNL transendothelial migration.
Human umbilical vein endothelial cell monolayers grown on filters were
stimulated for 3 h with various concentrations of LPS, and washed.
PMNL labelled with Sl Cr were added and allowed to migrate through the
monolayer for 75 min. Quantitation of PMNL transendothelial migration
is as in Methods. PMNL migration across unstimulated endothelium was
<3% and was subtracted from each value. Values are means -t-SEM of
three dose-response experiments performed with triplicate replicates.
The effect of LPS on PMNL migration across vascular
endothelium: The migration of PMNL into in-
flammatory reactions involving IL-1 or TNF, are
believed to involve the IL-1 and TNF activation of
vascular endothelium to express adhesion molecules
for PMNL (reviewed in Ref. 9). Various authors
have shown that this activated endothelium
not only promotes PMNL adhesion but also PMNL
transendothelial migration in vitro.9’23 Gram nega-
tive bacterial LPS has also been show to activate
endothelium for adhesion of PMNL, but the role
of endothelium generated cytokines such as IL-1 or
TNF, which could directly activate the en-
dothelium, is not clear.
9 Therefore, the effect ofLPS
on PMNL interaction directly with vascular
endothelial cells was studied using an in vitro system
which allows quantitation of PMNL transendothe-
lial migration. Endothelium stimulated with LPS
for 3 h resulted in PMNL transendothelial mi-
gration as shown in Fig. 3, even though the LPS
was removed from the system. An LPS concentra-
tion of 0.3 ng/ml was sufficient to induce a maximal
response. These results are comparable to previous
findings using this system with IL-1 or TNF0 to
activate the endothelium, i.e. 2-4 h of stimulation
was optimal for observing PMNL transendothelial
migration and periods less than 2 h or longer than
8 h resulted in a decrease in the migration response
23
(and not shown). In contrast to the 3 h required to
activate endothelium with LPS for supporting this
transendothelial migration, PMNL migration
across the activated endothelium was rapid,
plateauing between 60 to 90 min (not shown) as it
was with IL-1 and TNF- induced PMNL
migration reported previously.
3 There was no
migration of PMNL in response to any of the
concentrations of LPS, in the absence of an
endothelial monolayer
24 (and not shown).
It has been shown previously that endothelium
can be activated to secrete cytokines such as IL-1,
IL-8 and possibly TNF.6’9 Therefore, the possibility
was examined that the observed effects of LPS may
have been due to the endogenous production of one
of these cytokines by the endothelium and
secondary activation of the endothelium in an
autocrine fashion for supporting PMNL migration.
Table I shows the effects of IL-1RA, and antibodies
to IL-1, IL-113, TNF- or IL-8 on LPS stimulated
PMNL transendothelial migration. The IL-1RA
and antibodies were present during the 3 h LPS
stimulation and also during the 75 min PMNL
migration, to ensure maximal neutralization of any
endogenously produced IL-1, TNF or IL-8.
Table 1. The effect of blocking L-1, TNF- and L-8 on
LPS activation of endothelium for PMNL transendothelial
migration
Blocking agent % Inhibition
of PMNL migration
IL-1RA (300 ng/ml) 8.0
mAb TNFo (500 NU/ml) 7.5
L- RA + mAb TNF 4.1
anti-lL-8 IgG 0
L-1 RA + mAb TNF + anti L-8 0
polyclonal antiserum to L- o, L- 1/, + 7.1
TNFo
Endothelial monolayers as in Fig. were stimulated with
LPS (1 ng/ml) for 3 h in the presence of blocking agents or
non-immune serum. After the medium was exchanged prior to
the PMNL migration stage, the agents were added back and
were present throughout the assay. Polyclonal antisera were
used at 1:100 dilution, the predetermined dilution shown to
completely block the activities of exogenously added L-1,
IL-I, TNF and IL-8 in separate PMNL transendothelial
migration assays (not shown). Similarly the mAb to TNF= and
the L-1RA concentrations completely blocked activation of
endothelium by TNF= (10 U/ml) or IL-I= (0.3 ng/ml). Values
are means of two experiments for each condition.
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Although the antibodies to TNF-, IL-1, IL-8 and
IL-1RA each effectively blocked (>95%) PMNL
migration induced by the corresponding exogen-
ously applied cytokine (not shown), the LPS
induced activation of endothelium for PMNL
transendothelial migration was not significantly
inhibited by any of the agents even in combination.
Discussion
The major findings in this study are that IL-1RA
and mAb to TNF inhibited PMNL accumulation
in inflammatory reactions induced in the dermis by
killed E. coli, mAb to TNF inhibited the LPS
reaction but, even in combination, these agents only
partially inhibited PMNL accumulation in these
reactions (Fig. 1). This finding was surprising
because IL-1 and TNF- induce PMNL infiltration
into the skin upon intradermal injection and they
have synergistic effects. 3’4 The results suggest that
endogenous production of TNF, at least in dermal
inflammation may be more important than IL-1 in
LPS and perhaps also in E. coli inflammatory
reactions, the latter being partly dependent on LPS
shed from the cell wall of the bacteria.24 Another
explanation for our results, namely that IL-1RA
may not be active as an antagonist of the rabbit IL-1
receptor, is unlikely because the human 1L-1RA
effectively inhibited the PMNL accumulation in
rabbit skin induced by i.d. injection of IL-1 and
IL-lfl and systemic or local treatment in various
species with human IL-1RA has inhibited PMNL
infiltration e.g. in LPS induced alveolitis in rats and
immune complex colitis in rabbits. 1’25’26 The
relative lack of effect ofIL-1RA in our experiments,
in comparison to these other models is unlikely to
be due to the doses employed because concentra-
tions of up to 1000ng per site had no greater
inhibitory effect than 200 ng (not shown). Since our
mAb neutralizes both and fl species of TNF, it is
not possible from these results to conclude that
neutralization of TNF- was responsible for the
observed inhibition. However, TNF-fl is produced
primarily by activated lymphocytes
7 of which there
are relatively few in the skin during the acute
(< 3 h) phase of inflammation,iv
The differences observed in our experiments with
IL-1RA and other inflammation models in which
1L-1 appears to play an important role in PMNL
recruitment to LPS, for example in peritonitis
28 or
alveolitis2s’29 may be dependent on the tissue and
the type of resident cells, especially macrophages
available to secrete IL-1, a cytokine which is not
readily secreted by all types of macrophages and is
released slower or later than TNF-o.8’3’31 Among
skin cells, keratinocytes are known to store IL-1
but apparently do not release this except perhaps
upon cellular injury.
32 Langerhans cells have been
shown to secrete IL-1 and TNF-oq and mast ceils
have recently been shown to secrete preformed
stores of TNF-.33’34 Secretion of TNF- in skin
from these cells may occur more rapidly than of
IL-1, perhaps accounting for the greater apparent
contribution of TNF to PMNL infiltration in the
initial 3 h of the reaction. This conclusion is also
supported by the observations that TNF- is
secreted more rapidly (< 1 h) than IL-1 in response
to LPS injection systemically
35 or LPS in the
cerebrospinal fluid.36
Additional findings in the dermal inflammation
model reported here suggest that neither en-
dogenous production of IL-1 nor TNF contribute
to the PMNL infiltration induced by in situ immune
complex formation, as in the reversed passive
Arthus vasculitis reaction or by zymosan particles
(Fig. 2). This is not surprising in that both these
reactions are primarily dependent on complement
activation15’3v and likely require the generation of
C5aaesArg tO induce PMNL accumulation. The
PMNL recruiting activities of ZAP, which is
14 known to be due to C5aae arg, was not inhibited
by IL-1RA or by mAb to TNF, as expected and
this stimulus served primarily as a negative control
and an internal standard.
Finally, the results in Fig. 1 suggest that for
LPS and E. coli dermal inflammatory reactions
endogenous IL-1 and TNF play minor roles in
PMNL recruitment and that additional mechanisms
are operative. The killed E. call reaction is complex
and involves, in part, complement activation by the
cell wall of the bacterium with the generation of
C5aa Arg chemotactic activity as well as the release
of LPS from the cell wall of the bacterium, which
has no direct PMNL chemotactic properties.
14 The
response to LPS is also complex. However, two
mechanisms can largely be excluded: (a) the LPS
used here and at the nanogram concentrations
which induce intense inflammatory reactions, has
been shown previously not to activate the
complement pathway or to generate chemotactic
activity for PMNL;
24 and (b) the LPS was not
directly chemotactic and did not induce PMNL
migration in vitro in the abscence of an en-
dothelium.24 Endotoxin (LPS) of course is known
to be a potent inducer of IL-1 and TNF-o
production4’6-s’35 and via the action of these
cytokines could recruit PMNL. In addition, LPS,
IL-1 and TNFo all can induce endothelium to
produce the PMNL chemotactic cytokine, IL-8,
which is also produced by connective tissue cells
such as fibroblasts in response to IL-1 or TNF-
(but not LPS). 6’8 However, the present findings
demonstrate that LPS also can directly activate
endothelial cells to promote PMNL transendothe-
lial migration (Fig. 3). This action of LPS, at
concentrations <1 ng/ml, does not appear to
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involve IL-1, TNF-z or IL-8 production by the
endothelial cells (Table 1). Such a direct effect of
LPS on the microvasculature could, in part explain
why only partial inhibition in vivo of PMNL
infiltration by the TNF mAb and IL-1RA was
observed in these studies and in other LPS induced
inflammation models such as in pulmonary
inflammation.
25 However, additional cytokines may
also be involved in the LPS response such as the
45 kDa protein, previously reported to be produced
by LPS stimulated rabbit and human macrophages,
which is also active in recruiting PMNL into the
tissues. 18 These conclusions of alternate IL-1 and
TNF- independent LPS induced mechanisms for
PMNL recruitment are supported by most recent
observations with LPS induced inflammation in
monkey skin,
38 demonstrating that in vivo the
endothelium expresses the leukocyte adhesion
molecule-E selectin and PMNL infiltration occurs
prior to immunohistochemical evidence of IL-1 and
TNF<z production.
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